Diesel Takes Wearables To Fresh Peaks Originating Next Generation Touchscreen Smartwatch

Diesel advances its wearable technology to fresh peaks with the launch of the Full Guard 2.5 touchscreen smartwatch. This next generation smartwatch features innovative wearable technology, including heart rate tracking, NFC payment capabilities, and GPS tracking. Encased in Diesel's signature bold moto-inspired design, the new smartwatches signal to the world that fading into the crowd is not a choice. 
      
The new Diesel Full Guard 2.5 touchscreen smartwatch, compatible with both iPhone® and Android™ phones, is powered with Wear OS by Google and the Qualcomm® Snapdragon Wear™ 2100 SoC. Diesel has also enhanced the rapid charging, music control, customizable watch faces, and smartphone notification features.
      
Now for the details:
      
Heart Rate Tracking: naturally track your heart rate across all types of workouts using Google Fit or third-party apps 
      
Payment Technology: make purchases via your NFC-enabled smartwatch using Google Pay
     
GPS Distance Tracking: leave your phone at home when going for a walk, hike, ride, or run with built-in GPS that records the distance right on your smartwatch 
      
Assist on the Wrist: ask questions and give commands directly to your smartwatch via Google Assistant 
      
This new assemblage features four distinct styles: a matte steel case on a black leather strap, a gunmetal steel case on a brown leather strap, a matte black steel case on a black silicone strap and an all-over gunmetal stainless steel case on a three-link bracelet. Customizable dials include the neon Flicker dial, which shifts colors naturally throughout the day, and the interactive heart rate dial, which generates a rippling wavelike effect with the tap of a finger. 
      
The Diesel Full Guard 2.5 smartwatch will be available in select stores and at Diesel.com beginning October 2018.

Comments

Post a Comment

Popular posts from this blog

Pepsi Buys Rockstar

Pepsi buys Rockstar .     P epsiCo buys Rockstar Energy Beverages for $3.85 billion.     Founded in 2001, Rockstar is drinks designed for people leading an active lifestyle. Available in 20 flavors at convenience and grocery stores in 30 countries. Distributed by PepsiCo in North America since 2009. Supporting the Rockstar lifestyle across the globe through action sports, motorsports, and live music. Pepsi's energy portfolio also includes Kickstart , GameFuel, and Amp Energy.     The deal reflects the shift from reliance on sales of sugary, fizzy drinks toward options ranging from tea and coffee to still and sparkling water varieties, which appeal to health-conscious and younger consumers. Neither PepsiCo nor Coca-Cola owns a major brand in the energy drinks category, which is forecast to grow to more than $80 billion over the next five years and is now dominated by Red Bull.     2 00 countries and territories around the world enjoy ...
Read more

Compass Buys Marucci

Compass buys Marucci.     Compass Diversified Holdings buys Marucci Sports for $200 million.     Marucci Sports was founded in 2009 by Kurt Ainsworth, a retired pitcher for the San Francisco Giants and Baltimore Orioles, Joe Lawrence, a former second baseman for the Toronto Blue Jays, and Reed Dickens, a former White House Assistant Press Secretary under George W. Bush.     Marucci ’s first buy was Marucci Bat Company, launched out of a backyard shed in 2004. Ainsworth then led the buyout of an Amish-run Pennsylvania wood mill in 2008. This solidified Marucci's superior wood supply, and it still supplies all Marucci's wood today. In 2017 Marucci bought Victus , a baseball equipment maker known for its edgy designs and big attitude.     With vertically cohesive wood bat production, a global supplier group, and a client base of MVPs and World Series winners, Marucci and Victus are the top two bats among Big League players. T...
Read more

Gilead Buys Forty Seven

Gilead buys Forty Seven.     Gilead Sciences buys Forty Seven for $4.9 billion.     Forty Seven is a clinical-stage immuno-oncology firm developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on tech licensed from Stanford. Forty Seven’s lead program, magrolimab , is a monoclonal antibody against the CD47 receptor, a ‘don’t eat me’ signal that cancer cells commandeer to avoid being ingested by macrophages. Evaluated ant ibodies are in many clinical studies of patients with myelodysplastic syndrome, acute myeloid leukemia, non-Hodgkin lymphoma, and solid tumors. These assets complement the cell therapy franchise Gilead added with its 2017 buy of Kite Pharma .     Beyond magrolimab , Forty Seven is fixing to advance two more compounds into clinical testing. Developing FSI-174, an anti-cKIT antibody, in combination with magrolimab creates a novel, all-antibody conditioning regimen to address ...
Read more